Back to Search
JAVIER CANON, M.D.
M.D.
Pain Medicine (Psychiatry & Neurology) Physician
NPI: 1518938497Individual
Specialties, Licenses & Credentials
Pain Medicine (Psychiatry & Neurology) PhysicianPrimary
Psychiatry & Neurology — Pain Medicine
Code: 2084P2900X
L8573(TX)
Research & Publications (20)
Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.
PMID 19406901·Ann Oncol·2009
3-trial
Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis.
PMID 18064531·Clin Exp Metastasis·2008
7-preclinical
An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy.
PMID 17785764·Ann Oncol·2008
3-trial
Agrobacterium radiobacter bacteremia in oncologic and geriatric patients: presentation of two cases and review of the literature.
PMID 18539494·Int J Infect Dis·2008
5-case
RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis.
PMID 18606716·Mol Cancer Ther·2008
7-preclinical
Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer.
PMID 17208931·Ann Oncol·2007
3-trial
Nodular regenerative hyperplasia: a deleterious consequence of chemotherapy for colorectal liver metastases?
PMID 17696932·Liver Int·2007
8-other
Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study.
PMID 17005582·Eur Respir J·2007
8-other
A randomized, controlled trial comparing darbepoetin alfa correction/maintenance dosing with weekly dosing for treating chemotherapy-induced anemia.
PMID 17559735·Curr Med Res Opin·2007
3-trial
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.
PMID 17470858·J Clin Oncol·2007
3-trial
Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC).
PMID 17251007·Eur J Cancer·2007
8-other
Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia.
PMID 16478746·J Natl Cancer Inst·2006
3-trial
Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.
PMID 17116941·J Clin Oncol·2006
4-observational
Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group.
PMID 16877722·J Clin Oncol·2006
3-trial
Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study.
PMID 16219623·Ann Oncol·2005
3-trial
Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancer.
PMID 15868384·Invest New Drugs·2005
3-trial
High-dose oral medroxyprogesterone acetate or tamoxifen as adjuvant hormone therapy for node-negative early-stage breast cancer: randomized trial with 7-year update.
PMID 15245618·Clin Breast Cancer·2004
3-trial
A transcriptional chain linking eye specification to terminal determination of cone cells in the Drosophila eye.
PMID 14597205·Dev Biol·2003
7-preclinical
Gemcitabine combined with cisplatin as first-line treatment in patients with epithelial ovarian cancer: a phase II study.
PMID 14529659·Gynecol Oncol·2003
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 22001 SOUTHWEST FWY STE 300
RICHMOND, TX 77469 - Phone
- (281) 633-4940
Quick Facts
- NPI
- 1518938497
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile